{
    "clinical_study": {
        "@rank": "70675", 
        "arm_group": [
            {
                "arm_group_label": "Ramosetron", 
                "arm_group_type": "Experimental", 
                "description": "Intravenous administration of ramosetron 0.3 mg before the induction of general anesthesia"
            }, 
            {
                "arm_group_label": "Control", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Intravenous administration of 2ml normal saline before the induction of general anesthesia"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effects of ramosetron on corrected QT interval in\n      patients undergoing off pump coronary artery bypass surgery."
        }, 
        "brief_title": "The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Coronary Artery Bypass Graft Triple Vessel", 
            "Hypotension"
        ], 
        "condition_browse": {
            "mesh_term": "Hypotension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Elective off-pump coronary artery bypass graft surgery\n\n        Exclusion Criteria:\n\n          -  Emergency operation\n\n          -  preoperative use of any inotropics or mechanical assist device\n\n          -  severe liver disease (>Child class II)\n\n          -  dialysis dependent renal failure\n\n          -  Left ventricular ejection fraction <30 %\n\n          -  Combined major surgery like carotid endarterectomy\n\n          -  Previous allergy history to any 5-hydroxytryptamine type 3 (5-HT3) antagonist\n\n          -  Preoperative QT prolongation ( 500 >msec) or arrhythmia"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "116", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02139241", 
            "org_study_id": "Ramosetron_opcab"
        }, 
        "intervention": [
            {
                "arm_group_label": "Ramosetron", 
                "description": "0.3 mg IV as bolus before induction of general anesthesia", 
                "intervention_name": "Ramosetron", 
                "intervention_type": "Drug", 
                "other_name": "Nasea"
            }, 
            {
                "arm_group_label": "Control", 
                "description": "2 ml normal saline as bolus before induction of general anesthesia", 
                "intervention_name": "Normal saline", 
                "intervention_type": "Drug", 
                "other_name": "Normal saline"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ramosetron"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "jeonyunseok@gmail.com", 
                "last_name": "Yunseok Jeon, PhD", 
                "phone": "82-2-2072-2467"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Efficacy and Safety of Ramosetron in Patients Undergoing Off Pump Coronary Artery Bypass Surgery", 
        "overall_contact": {
            "email": "jeonyunseok@gmail.com", 
            "last_name": "Yunseok Jeon, PhD", 
            "phone": "82-2-2072-2467"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "at 1,2,3,5,10,15,30,45,60,90,120,240 minutes after ramosetron injection, at the time of operation end, ICU 12hour", 
            "measure": "corrected QT interval (QTc interval)", 
            "safety_issue": "Yes", 
            "time_frame": "up to 240 minutes after induction of general anesthesia"
        }, 
        "reference": [
            {
                "PMID": "19261954", 
                "citation": "Havrilla PL, Kane-Gill SL, Verrico MM, Seybert AL, Reis SE. Coronary vasospasm and atrial fibrillation associated with ondansetron therapy. Ann Pharmacother. 2009 Mar;43(3):532-6. doi: 10.1345/aph.1L544. Epub 2009 Mar 3."
            }, 
            {
                "PMID": "22100822", 
                "citation": "Sahoo T, SenDasgupta C, Goswami A, Hazra A. Reduction in spinal-induced hypotension with ondansetron in parturients undergoing caesarean section: a double-blind randomised, placebo-controlled study. Int J Obstet Anesth. 2012 Jan;21(1):24-8. doi: 10.1016/j.ijoa.2011.08.002. Epub 2011 Nov 18."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02139241"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "hypotension or bradycardia during the peri-induction period and the coronary anastomosis period", 
                "safety_issue": "Yes", 
                "time_frame": "up to 240 minutes after induction of general anesthesia"
            }, 
            {
                "measure": "incidence of postoperative atrial fibrillation", 
                "safety_issue": "Yes", 
                "time_frame": "during the hospital stay (from ICU admission to hospital discharge, average of 1 week)"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}